Abschlußbericht

Studientitel:

TRANSLATIONAL THERAPY IN PATIENTS WITH OSTEOGENESIS IMPERFECTA

–

Sponsor der klinischen Prüfung

	Translational therapy in patients

	mone, N-Telopeptides, Osteocalcin) are measured to describe the bone resorption by osteoclasts and to determine after how much time osteoclastic activity increases after the injection. • Mobility

	12 weeks. DPD after denosumab injection at day 1, 2, 4, 8, 14, 21, 28, 42, 56, 70

	Contraindications: Hypocalcemia
Behandlung/Intervention	*Den*[redacted]

	therapeutic effect under investigation
Darstellung der Demogra-	11 children were screened for partic[illegible]

	rise. Mean levels are shown for visit 1-6 in figure 2C/D/E/F. Vit-

[redacted]

	priate. Cumulative lists of adverse events (AEs) and serious

further studies in larger (multicentre)

[redacted]

Table 2. Ch

(m)

Figure 1A/B: Individual changes of lumbar spine vertebrae 2-4 areal bone mineral density and Z-scores between baseline (week 0) and week 48



Figure 2 A-F: Courses of bone metabolism markers within the trial



Figure 3: Individual changes of Motor Function (GMFM-88, One-minute walking distance) between baseline, week 24, and study week 48

[redacted]